Precision Biosciences Stock Price, News & Analysis

Precision BioSciences (DTIL) has presented preclinical data for PBGENE-HBV, its gene editing therapy for chronic hepatitis B, and outlined its Phase 1 ELIMINATE-B trial design. The preclinical data showed 99% viral DNA editing in non-human primates, effective hepatocyte distribution, and sustained declines in viral biomarkers. The ELIMINATE-B trial will evaluate up to 45 HBeAg-negative patients across five countries, with data expected throughout 2025. The company has received clearance to begin trials in Moldova, with additional regulatory applications pending. The therapy targets approximately 300 million people globally affected by chronic hepatitis B, addressing an unmet need in a multi-billion-dollar market where current treatments achieve functional cure in less than 3% of patients.

Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, announced it will release its financial results for the third quarter of 2024 on November 4, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies aimed at sophisticated gene edits. Along with the financial results, Precision BioSciences will also provide a business update.

Precision BioSciences (Nasdaq: DTIL) announced a virtual Hepatitis B Investor Event scheduled for November 15, 2024. The event will feature Key Opinion Leaders and members of Precision's Hepatitis Scientific Advisory Board discussing the current hepatitis B treatment landscape, which only achieves 1-3% functional cure rates. The presentation will focus on PBGENE-HBV, their gene editing approach targeting cccDNA elimination and HBV DNA inactivation. The company will present final preclinical safety data and phase 1 clinical trial plans following Clinical Trial Application approval in Moldova.

Precision BioSciences (Nasdaq: DTIL) presented preclinical data at the ESGCT 31st Annual Congress showcasing their ARCUS platform's capability for high-efficiency gene editing through homology-directed repair (HDR). The research demonstrated gene insertion rates exceeding 85% in T cells and 39% in non-dividing primary human hepatocytes.

The ARCUS platform showed versatility in DNA editing, achieving all twelve possible base changes, specific base removal and insertions, and whole gene replacements. This capability extends beyond current limitations of base editors and prime editors, potentially offering broader therapeutic applications for diseases requiring function restoration.

Precision BioSciences (NASDAQ: DTIL) has received its first Clinical Trial Application (CTA) approval in Moldova for PBGENE-HBV, marking the first in vivo gene editing program for chronic hepatitis B virus to enter global clinical trials. The program aims to cure chronic hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA in hepatocytes using the proprietary ARCUS® platform. PBGENE-HBV delivers nuclease-encoding mRNA to the liver via lipid nanoparticles, targeting the HBV viral genome. The company is pursuing additional CTA and IND approvals globally to accelerate trial enrollment, aiming to provide a potential cure for nearly 300 million patients living with chronic hepatitis B.

Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, has announced its participation in two upcoming investor conferences. The company will be part of a panel discussion titled 'Expanding Platform Potential' at the Longwood Boston CEO Conference on October 28, 2024, at 11:10 AM ET.

Additionally, Precision BioSciences will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 11, 2024, at 3:00 PM ET at the InterContinental Boston. A live webcast of this event will be available on the company's website, with an archived replay accessible for approximately 30 days after the event.

Precision BioSciences utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.

Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, announced a poster presentation at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress in Rome, Italy, from October 22-25, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion.

The presentation, titled 'High-efficiency homology-directed insertion into the genome using engineered homing endonucleases', will be delivered by Dr. Adam Mischler, Senior Scientist at Precision BioSciences Gene Discovery. The poster (Number #PO678) will be presented on Thursday, October 24, 2024, from 6:00-7:30pm CEST. This presentation highlights Precision BioSciences' advancements in gene editing technology, particularly in addressing diseases where a defective gene requires the expression of a new DNA sequence.

Precision BioSciences (Nasdaq: DTIL), an advanced gene editing company, has announced its participation in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on October 8, 2024. The company, which utilizes its proprietary ARCUS® platform for developing in vivo gene editing therapies, will present during a fireside chat at 11:00 AM ET.

The presentation will be accessible via webcast, with registration available through a provided link. Investors can also view the presentation on Precision's website under the Investors section, Events & Presentations. An archived replay will be available for approximately 30 days after the event.

Precision BioSciences (Nasdaq: DTIL) has submitted Clinical Trial Applications (CTA) to initiate a Phase 1 study for PBGENE-HBV, its in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV). The therapy aims to eliminate cccDNA, the key source of replicating HBV, while also inactivating integrated HBV DNA in hepatocytes.

This marks the first gene editing approach for chronic hepatitis B, targeting an estimated 300 million people globally affected by the disease. The company's regulatory package is supported by robust non-human primate safety studies and efficacy in numerous preclinical models. Precision BioSciences plans to initiate the global Phase 1 trial soon and expects to report data in 2025.